Compare ONC & KB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONC | KB |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Switzerland | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8B | 31.3B |
| IPO Year | N/A | N/A |
| Metric | ONC | KB |
|---|---|---|
| Price | $353.92 | $104.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $370.25 | N/A |
| AVG Volume (30 Days) | ★ 293.5K | 237.0K |
| Earning Date | 02-26-2026 | 02-06-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | N/A | ★ 20.12 |
| EPS | 0.58 | ★ 10.59 |
| Revenue | $4,972,687,000.00 | ★ $10,794,642,823.00 |
| Revenue This Year | $895.40 | $17.52 |
| Revenue Next Year | $22.04 | $2.13 |
| P/E Ratio | $571.32 | ★ $8.68 |
| Revenue Growth | ★ 50.43 | 3.82 |
| 52 Week Low | $196.45 | $46.38 |
| 52 Week High | $385.22 | $104.84 |
| Indicator | ONC | KB |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | N/A |
| Support Level | $328.91 | N/A |
| Resistance Level | $355.43 | N/A |
| Average True Range (ATR) | 9.27 | 0.00 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 65.61 | 0.00 |
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.